Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

One of the main topics of conversation at the beginning of 2025 is how pharma companies should build their pipelines and the rising role that China is playing. A widely-cited report from Stifel show

Acepodia is emerging as one of the world’s few developers of antibody-drug conjugates (ADCs) preparing to advance into the clinic with a dual payload-fixed design of targeted cancer therapy. Based out

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Partners With UK’s Alchemab On A

Biopharmaceutical companies remained on the hunt for cancer antibody-drug conjugate assets this summer, as deals revolving around ADCs accounted for five of 12 cancer-related deals, according to Biome